Therabron Therapeutics Makes Strategic Changes and Expands Management Team

Dec 10, 2015, 08:30 ET from Therabron Therapeutics, Inc.

ROCKVILLE, Md., Dec. 10, 2015 /PRNewswire/ -- Therabron Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing a new standard in respiratory care, today announced new appointments and changes to the Company's management team.  Effective immediately, Dr. Thomas F. Miller has been promoted to President & Chief Executive Officer.   Dr. Aprile Pilon has assumed responsibility for leading and advancing the Company's secretoglobin platform in the role of Executive Vice President and Chief Scientific Officer. Therabron has also named Anita Fauchier as its Vice President of Regulatory Affairs and Quality Assurance.  Dr. Pilon and Ms. Fauchier will report to Dr. Miller, effective immediately.

"I am honored to have the opportunity to assume this role at Therabron, a company committed to generating transformative therapies in the respiratory care space.  Dr. Pilon's contributions to our understanding of the field of secretoglobin biology and pharmacology are unparalleled and I am fortunate to have the opportunity to work with and learn from her", said Dr. Miller. "Given Ms. Fauchier's proven track record of performance and regulatory affairs and quality leadership, I am confident that her contributions will have a meaningful impact on the future success of Therabron as well."

Dr. Miller brings 20 years of relevant pharmaceutical, biotechnology and medical device development and commercialization experience to Therabron.  He initially joined the company in April 2014 in the capacity of President and Chief Operating Officer.  Prior to joining Therabron, Dr. Miller spent ten years with Discovery Laboratories, Inc., with his professional tenure culminating in his role as the company's Senior Vice President and Chief Operating Officer.  Prior to Discovery Labs, Dr. Miller served in commercial and clinical development roles of increasing responsibility at Johnson & Johnson, Pharmacia, BASF Healthcare, Novartis and Pfizer.  In addition to his appointment as President and Chief Executive Officer, Dr. Miller has also been nominated to join the company's board of directors.

Dr. Pilon has assumed the role of Therabron's Executive Vice President and Chief Scientific Officer.  Dr. Pilon, the Company's Founder, has had a career-long focus on the advancement of secretoglobin protein biology and pharmacology, and the development of secretoglobin therapeutic candidates.  Her scientific endeavors relating to secretoglobin biology began in the mid-90's through a collaboration with the U.S. National Institutes of Health.  Dr. Pilon is a recognized thought-leader and subject matter expert in the field of secretoglobin proteins and has authored several scientific publications and patents on the subject. Dr. Pilon is also a member of the Company's board of directors.

Ms. Fauchier has assumed the role of Therabron's Vice President of Regulatory Affairs and Quality Assurance.  Ms. Fauchier brings more than 20 years of relevant regulatory and quality assurance experience to Therabron.  Most recently, she served as Executive Director, Regulatory Affairs at Cempra Pharmaceuticals, Inc. where she was responsible for the compilation and submission of several regulatory dossiers to the U.S. Food and Drug Administration and multiple international health authorities.  Her substantial experience includes regulatory oversight of both early staged COPD and pediatric drug development programs.  Prior to Cempra, she held regulatory and quality assurance roles of increasing responsibility at the U.S. Department of Health and Human Services, Arbor Pharmaceuticals, Sanofi Aventis, USB Pharma, Purdue Pharma and Merck. 

About Therabron Therapeutics, Inc.

Therabron Therapeutics, Inc. is a clinical-stage biotechnology company, founded in 2007 and located in Rockville, MD.  Therabron is focused on the development of protein therapeutics to address respiratory disease. The company's product candidates aim to restore the natural immune balance in the lungs of respiratory patients through the administration of synthetic human CC10 proteins. The family of CC10 proteins, also known as secretoglobins, have the potential to change the course of acute and chronic respiratory diseases, representing large markets into which few truly novel drugs have been introduced. Therabron's product candidates have the potential to be first-in-class, disease-modifying, breakthrough biologic therapeutics. For additional information, please visit www.therabron.com.

SOURCE Therabron Therapeutics, Inc.



RELATED LINKS

http://www.therabron.com